A novel SARS-CoV-2 mRNA virus-like particle vaccine is highly potent and well tolerated in adults in a phase 1 randomized clinical trial

By combining mRNA vaccine technology with VLP-based antigen display, we developed two candidate SARS-CoV-2 vaccines, AZD9838 and AZD6563, that were well tolerated versus a licensed mRNA vaccine, BNT162b2. Furthermore, the variant-matched AZD6563 generated a similar immunogenicity to BNT162b2 but at one third of the dosage (10 μg versus 30 μg).

Authors

Institutions

Publication Details

Journal
Vaccine
Published
2026-02-10
DOI
https://doi.org/10.1016/j.vaccine.2026.128304
Primary Topic
SARS-CoV-2 and COVID-19 Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A novel SARS-CoV-2 mRNA virus-like particle vaccine is highly potent and well tolerated in adults in a phase 1 randomized clinical trial

Rachel Park, Ann Marie Stanley, J. Lee, Stacey Cromer Berman et al.
Vaccine
SARS-CoV-2 and COVID-19 Research
article

A novel SARS-CoV-2 mRNA virus-like particle vaccine is highly potent and well tolerated in adults in a phase 1 randomized clinical trial

Rachel Park, Ann Marie Stanley, J. Lee, Stacey Cromer Berman, Brett Jepson, Apinya Vutikullird, Lawrence Sher, Lee-Jah Chang, Kelly Morales, Cindy Handelsman, Abby Isaacs, Manish Jain, Kathryn Shoemaker
article en

Abstract

By combining mRNA vaccine technology with VLP-based antigen display, we developed two candidate SARS-CoV-2 vaccines, AZD9838 and AZD6563, that were well tolerated versus a licensed mRNA vaccine, BNT162b2. Furthermore, the variant-matched AZD6563 generated a similar immunogenicity to BNT162b2 but at one third of the dosage (10 μg versus 30 μg).

VaccineVol. 76
Coastal Carolina University (US), AstraZeneca (South Korea) (KR), AstraZeneca (France) (FR), AstraZeneca (Netherlands) (NL), The Ark (IE), Peninsula Research (US), AstraZeneca (Switzerland) (CH), AstraZeneca (Poland) (PL), AstraZeneca (Canada) (CA), Nagoya Kyouritsu Hospital (JP)
Good health and well-being
Openalex Percentile: Top 62%
SARS-CoV-2 and COVID-19 Research
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

A novel SARS-CoV-2 mRNA virus-like particle vaccine is highly potent and well tolerated in adults in a phase 1 randomized clinical trial — Rachel Park, Ann Marie Stanley, et al. · Vaccine (2026) | TGRS Research Map | TGRS